INmune Bio Statistics

Total Valuation

INmune Bio has a market cap or net worth of $184.36 million. The enterprise value is $163.82 million.

Market Cap	184.36M
Enterprise Value	163.82M

Important Dates

The next estimated earnings date is Thursday, May 8, 2025, after market close.

Earnings Date	May 8, 2025
Ex-Dividend Date	n/a

Share Statistics

INmune Bio has 22.93 million shares outstanding. The number of shares has increased by 10.92% in one year.

Current Share Class	22.93M
Shares Outstanding	22.93M
Shares Change (YoY)	+10.92%
Shares Change (QoQ)	+10.21%
Owned by Insiders (%)	19.72%
Owned by Institutions (%)	27.46%
Float	14.93M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	13,168.55
Forward PS	n/a
PB Ratio	5.58
P/TBV Ratio	11.83
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	11,701.55
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.14, with a Debt / Equity ratio of 0.01.

Current Ratio	3.14
Quick Ratio	3.09
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-54.04

Financial Efficiency

Return on equity (ROE) is -119.83% and return on invested capital (ROIC) is -65.75%.

Return on Equity (ROE)	-119.83%
Return on Assets (ROA)	-55.19%
Return on Invested Capital (ROIC)	-65.75%
Return on Capital Employed (ROCE)	-131.83%
Revenue Per Employee	$636
Profits Per Employee	-$1.91M
Employee Count	22
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -21.30% in the last 52 weeks. The beta is 1.88, so INmune Bio's price volatility has been higher than the market average.

Beta (5Y)	1.88
52-Week Price Change	-21.30%
50-Day Moving Average	7.98
200-Day Moving Average	6.76
Relative Strength Index (RSI)	53.97
Average Volume (20 Days)	290,446

Short Selling Information

The latest short interest is 6.06 million, so 26.43% of the outstanding shares have been sold short.

Short Interest	6.06M
Short Previous Month	5.58M
Short % of Shares Out	26.43%
Short % of Float	40.58%
Short Ratio (days to cover)	23.33

Income Statement

In the last 12 months, INmune Bio had revenue of $14,000 and -$42.08 million in losses. Loss per share was -$2.11.

Revenue	14,000
Gross Profit	14,000
Operating Income	-42.64M
Pretax Income	-37.74M
Net Income	-42.08M
EBITDA	n/a
EBIT	-42.64M
Loss Per Share	-$2.11

Full Income Statement

Balance Sheet

The company has $20.92 million in cash and $384,000 in debt, giving a net cash position of $20.54 million or $0.90 per share.

Cash & Cash Equivalents	20.92M
Total Debt	384,000
Net Cash	20.54M
Net Cash Per Share	$0.90
Equity (Book Value)	32.10M
Book Value Per Share	1.44
Working Capital	15.44M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-33.36M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	100.00%
Operating Margin	-304,535.71%
Pretax Margin	-300,585.71%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

INmune Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-10.92%
Shareholder Yield	-10.92%
Earnings Yield	-22.83%
FCF Yield	n/a

Analyst Forecast

The average price target for INmune Bio is $24.33, which is 204.89% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$24.33
Price Target Difference	204.89%
Analyst Consensus	Strong Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	537.27%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

INmune Bio has an Altman Z-Score of 4.46 and a Piotroski F-Score of 2.

Altman Z-Score	4.46
Piotroski F-Score	2